Top

Published in:

01-06-2012 | NON-THEMATIC REVIEW

Cancer stem cells and EMT in carcinoma

Authors: Adrian Biddle, Ian C. Mackenzie

Published in: Cancer and Metastasis Reviews | Issue 1-2/2012

Abstract

The majority of deaths from carcinoma are caused by secondary growths that result from tumour invasion and metastasis. The importance of epithelial-to-mesenchymal transition (EMT) as a driver of invasion and metastasis is increasingly recognised, and recent evidence has highlighted a link between EMT and the cancer stem cells that initiate and maintain tumours and have also been implicated in invasion and metastasis. Here, we review cancer stem cells and their link with EMT, and explore the importance of this link in metastasis and therapeutic resistance of tumours. We also discuss new evidence from our laboratory demonstrating that cancer stem cells display a remarkable phenotypic plasticity that enables them to switch between an epithelial phenotype that drives tumour growth and an EMT phenotype that drives metastasis. As successful therapies must eradicate cancer stem cells in all their guises, the identification of sub-types of cancer stem cells that display therapeutic resistance and phenotypic plasticity has important implications for the future design of therapeutic strategies. The ability to assay the responses of different cancer stem cell phenotypes in vitro holds promise for the rapid development of a new generation of targeted therapies that fulfil this objective.

Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133(4), 704–715. doi:10.1016/j.cell.2008.03.027.PubMedCrossRef

Brabletz, T., Jung, A., Spaderna, S., Hlubek, F., & Kirchner, T. (2005). Opinion: Migrating cancer stem cells—An integrated concept of malignant tumour progression. Nature Reviews. Cancer, 5(9), 744–749. doi:10.1038/nrc1694.PubMedCrossRef

Biddle, A., Liang, X., Gammon, L., Fazil, B., Harper, L. J., Emich, H., et al. (2011). Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Research. doi:10.1158/0008-5472.CAN-11-1059.

Chaffer, C. L., Brennan, J. P., Slavin, J. L., Blick, T., Thompson, E. W., & Williams, E. D. (2006). Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: Role of fibroblast growth factor receptor-2. Cancer Research, 66(23), 11271–11278. doi:10.1158/0008-5472.CAN-06-2044.PubMedCrossRef

Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., et al. (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 138(4), 645–659. doi:10.1016/j.cell.2009.06.034.PubMedCrossRef

Wang, Z., Li, Y., Ahmad, A., Azmi, A. S., Kong, D., Banerjee, S., et al. (2010). Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resistance Updates, 13(4–5), 109–118. doi:10.1016/j.drup.2010.07.001.PubMedCrossRef

Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H., Jones, D. L., et al. (2006). Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Research, 66(19), 9339–9344. doi:10.1158/0008-5472.CAN-06-3126.PubMedCrossRef

Gu, G., Yuan, J., Wills, M., & Kasper, S. (2007). Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Research, 67(10), 4807–4815. doi:10.1158/0008-5472.CAN-06-4608.PubMedCrossRef

Mackenzie, I. C. (2008). Cancer stem cells. Annals of Oncology, 19(Suppl 5), v40–v43. doi:10.1093/annonc/mdn306.PubMedCrossRef

10.

Mackenzie, I. C. (2006). Stem cell properties and epithelial malignancies. European Journal of Cancer, 42(9), 1204–1212. doi:10.1016/j.ejca.2006.01.041.PubMedCrossRef

11.

Morgan, J. E., & Partridge, T. A. (2003). Muscle satellite cells. The International Journal of Biochemistry & Cell Biology, 35(8), 1151–1156.CrossRef

12.

Stingl, J. (2009). Detection and analysis of mammary gland stem cells. The Journal of Pathology, 217(2), 229–241. doi:10.1002/path.2457.PubMedCrossRef

13.

Battula, V. L., Evans, K. W., Hollier, B. G., Shi, Y., Marini, F. C., Ayyanan, A., et al. (2010). Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells, 28(8), 1435–1445. doi:10.1002/stem.467.PubMedCrossRef

14.

Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3(7), 730–737.PubMedCrossRef

15.

Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Research, 63(18), 5821–5828.PubMed

16.

Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100(7), 3983–3988. doi:10.1073/pnas.0530291100.PubMedCrossRef

17.

Locke, M., Heywood, M., Fawell, S., & Mackenzie, I. C. (2005). Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Research, 65(19), 8944–8950. doi:10.1158/0008-5472.CAN-05-0931.PubMedCrossRef

18.

Prince, M. E., Sivanandan, R., Kaczorowski, A., Wolf, G. T., Kaplan, M. J., Dalerba, P., et al. (2007). Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 104(3), 973–978. doi:10.1073/pnas.0610117104.PubMedCrossRef

19.

Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., et al. (2007). Identification of pancreatic cancer stem cells. Cancer Research, 67(3), 1030–1037. doi:10.1158/0008-5472.CAN-06-2030.PubMedCrossRef

20.

Patrawala, L., Calhoun, T., Schneider-Broussard, R., Li, H., Bhatia, B., Tang, S., et al. (2006). Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene, 25(12), 1696–1708. doi:10.1038/sj.onc.1209327.PubMedCrossRef

21.

Clay, M. R., Tabor, M., Owen, J. H., Carey, T. E., Bradford, C. R., Wolf, G. T., et al. (2010). Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head & Neck, 32(9), 1195–1201. doi:10.1002/hed.21315.CrossRef

22.

Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1(5), 555–567. doi:10.1016/j.stem.2007.08.014.PubMedCrossRef

23.

Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M. F., et al. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Journal of the National Cancer Institute, 100(9), 672–679. doi:10.1093/jnci/djn123.PubMedCrossRef

24.

Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444(7120), 756–760. doi:10.1038/nature05236.PubMedCrossRef

25.

Singh, A., & Settleman, J. (2010). EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene, 29(34), 4741–4751. doi:10.1038/onc.2010.215.PubMedCrossRef

26.

Charafe-Jauffret, E., Ginestier, C., Iovino, F., Tarpin, C., Diebel, M., Esterni, B., et al. (2010). Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clinical Cancer Research, 16(1), 45–55. doi:10.1158/1078-0432.CCR-09-1630.PubMedCrossRef

27.

Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1(3), 313–323. doi:10.1016/j.stem.2007.06.002.PubMedCrossRef

28.

Hay, E. D. (2005). The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Developmental Dynamics, 233(3), 706–720. doi:10.1002/dvdy.20345.PubMedCrossRef

29.

Savagner, P., Kusewitt, D. F., Carver, E. A., Magnino, F., Choi, C., Gridley, T., et al. (2005). Developmental transcription factor slug is required for effective re-epithelialization by adult keratinocytes. Journal of Cellular Physiology, 202(3), 858–866. doi:10.1002/jcp.20188.PubMedCrossRef

30.

Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation, 119(6), 1420–1428. doi:10.1172/JCI39104.PubMedCrossRef

31.

Wu, Y., Deng, J., Rychahou, P. G., Qiu, S., Evers, B. M., & Zhou, B. P. (2009). Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell, 15(5), 416–428. doi:10.1016/j.ccr.2009.03.016.PubMedCrossRef

32.

Yang, M. H., Wu, M. Z., Chiou, S. H., Chen, P. M., Chang, S. Y., Liu, C. J., et al. (2008). Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nature Cell Biology, 10(3), 295–305. doi:10.1038/ncb1691.PubMedCrossRef

33.

Gjerdrum, C., Tiron, C., Hoiby, T., Stefansson, I., Haugen, H., Sandal, T., et al. (2010). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America, 107(3), 1124–1129. doi:10.1073/pnas.0909333107.PubMedCrossRef

34.

Skvortsova, I., Skvortsov, S., Raju, U., Stasyk, T., Riesterer, O., Schottdorf, E. M., et al. (2010). Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse. Radiotherapy and Oncology, 96(1), 108–115. doi:10.1016/j.radonc.2010.04.017.PubMedCrossRef

35.

Bandyopadhyay, A., Wang, L., Agyin, J., Tang, Y., Lin, S., Yeh, I. T., et al. (2010). Doxorubicin in combination with a small TGFbeta inhibitor: A potential novel therapy for metastatic breast cancer in mouse models. PLoS One, 5(4), e10365. doi:10.1371/journal.pone.0010365.PubMedCrossRef

36.

Fuchs, B. C., Fujii, T., Dorfman, J. D., Goodwin, J. M., Zhu, A. X., Lanuti, M., et al. (2008). Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Research, 68(7), 2391–2399. doi:10.1158/0008-5472.CAN-07-2460.PubMedCrossRef

37.

Kudo-Saito, C., Shirako, H., Takeuchi, T., & Kawakami, Y. (2009). Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell, 15(3), 195–206. doi:10.1016/j.ccr.2009.01.023.PubMedCrossRef

38.

Shin, S. Y., Rath, O., Zebisch, A., Choo, S. M., Kolch, W., & Cho, K. H. (2010). Functional roles of multiple feedback loops in extracellular signal-regulated kinase and wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer Research, 70(17), 6715–6724. doi:10.1158/0008-5472.CAN-10-1377.PubMedCrossRef

39.

Smith, G. R., & Missailidis, S. (2004). Cancer, inflammation and the AT1 and AT2 receptors. Journal of Inflammation (London), 1(1), 3. doi:10.1186/1476-9255-1-3.CrossRef

40.

Chang, H. Y., Nuyten, D. S., Sneddon, J. B., Hastie, T., Tibshirani, R., Sorlie, T., et al. (2005). Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proceedings of the National Academy of Sciences of the United States of America, 102(10), 3738–3743. doi:10.1073/pnas.0409462102.PubMedCrossRef

41.

Thiery, J. P. (2003). Epithelial-mesenchymal transitions in development and pathologies. Current Opinion in Cell Biology, 15(6), 740–746.PubMedCrossRef

42.

Wellner, U., Schubert, J., Burk, U. C., Schmalhofer, O., Zhu, F., Sonntag, A., et al. (2009). The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nature Cell Biology, 11(12), 1487–1495. doi:10.1038/ncb1998.PubMedCrossRef

43.

Barrandon, Y., & Green, H. (1987). Three clonal types of keratinocyte with different capacities for multiplication. Proceedings of the National Academy of Sciences of the United States of America, 84(8), 2302–2306.PubMedCrossRef

44.

Harper, L. J., Piper, K., Common, J., Fortune, F., & Mackenzie, I. C. (2007). Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. Journal of Oral Pathology & Medicine, 36(10), 594–603. doi:10.1111/j.1600-0714.2007.00617.x.CrossRef

45.

Li, H., Chen, X., Calhoun-Davis, T., Claypool, K., & Tang, D. G. (2008). PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Research, 68(6), 1820–1825. doi:10.1158/0008-5472.CAN-07-5878.PubMedCrossRef

46.

Keller, P. J., Lin, A. F., Arendt, L. M., Klebba, I., Jones, A. D., Rudnick, J. A., et al. (2010). Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines. Breast Cancer Research, 12(5), R87. doi:10.1186/bcr2755.PubMedCrossRef

47.

Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., et al. (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Reports, 9(6), 582–589. doi:10.1038/embor.2008.74.PubMedCrossRef

48.

Chaffer, C. L., Brueckmann, I., Scheel, C., Kaestli, A. J., Wiggins, P. A., Rodrigues, L. O., et al. (2011). Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proceedings of the National Academy of Sciences of the United States of America, 108(19), 7950–7955. doi:10.1073/pnas.1102454108.PubMedCrossRef

49.

Gaggioli, C., Hooper, S., Hidalgo-Carcedo, C., Grosse, R., Marshall, J. F., Harrington, K., et al. (2007). Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nature Cell Biology, 9(12), 1392–1400. doi:10.1038/ncb1658.PubMedCrossRef

50.

Giampieri, S., Manning, C., Hooper, S., Jones, L., Hill, C. S., & Sahai, E. (2009). Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nature Cell Biology, 11(11), 1287–1296. doi:10.1038/ncb1973.PubMedCrossRef

51.

Asiedu, M. K., Ingle, J. N., Behrens, M. D., Radisky, D. C., & Knutson, K. L. (2011). TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Research, 71(13), 4707–4719. doi:10.1158/0008-5472.CAN-10-4554.PubMedCrossRef

52.

Korpal, M., Ell, B. J., Buffa, F. M., Ibrahim, T., Blanco, M. A., Celia-Terrassa, T., et al. (2011). Direct targeting of Sec23a by miR-200 s influences cancer cell secretome and promotes metastatic colonization. Nature Medicine, 17(9), 1101–1108. doi:10.1038/nm.2401.PubMedCrossRef

53.

Korpal, M., Lee, E. S., Hu, G., & Kang, Y. (2008). The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. Journal of Biological Chemistry, 283(22), 14910–14914. doi:10.1074/jbc.C800074200.PubMedCrossRef

54.

Olumi, A. F., Grossfeld, G. D., Hayward, S. W., Carroll, P. R., Tlsty, T. D., & Cunha, G. R. (1999). Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Research, 59(19), 5002–5011.PubMed

55.

Kojima, Y., Acar, A., Eaton, E. N., Mellody, K. T., Scheel, C., Ben-Porath, I., et al. (2010). Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 107(46), 20009–20014. doi:10.1073/pnas.1013805107.PubMedCrossRef

56.

Lopez-Novoa, J. M., & Nieto, M. A. (2009). Inflammation and EMT: An alliance towards organ fibrosis and cancer progression. EMBO Molecular Medicine, 1(6–7), 303–314. doi:10.1002/emmm.200900043.PubMedCrossRef

57.

Creighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V. M., Sjolund, A., et al. (2009). Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America, 106(33), 13820–13825. doi:10.1073/pnas.0905718106.PubMedCrossRef

58.

Harper, L. J., Costea, D. E., Gammon, L., Fazil, B., Biddle, A., & Mackenzie, I. C. (2010). Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer, 10, 166. doi:10.1186/1471-2407-10-166.PubMedCrossRef

59.

Surowiak, P., Materna, V., Kaplenko, I., Spaczynski, M., Dolinska-Krajewska, B., Gebarowska, E., et al. (2006). ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clinical Cancer Research, 12(23), 7149–7158. doi:10.1158/1078-0432.CCR-06-0564.PubMedCrossRef

60.

Theile, D., Ketabi-Kiyanvash, N., Herold-Mende, C., Dyckhoff, G., Efferth, T., Bertholet, V., et al. (2011). Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head & Neck, 33(7), 959–968. doi:10.1002/hed.21559.CrossRef

61.

Wang, X. Q., Ongkeko, W. M., Chen, L., Yang, Z. F., Lu, P., Chen, K. K., et al. (2010). Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology, 52(2), 528–539. doi:10.1002/hep.23692.PubMedCrossRef

62.

Tsai, L. L., Yu, C. C., Chang, Y. C., Yu, C. H., & Chou, M. Y. (2011). Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. Journal of Oral Pathology & Medicine. doi:10.1111/j.1600-0714.2011.01015.x.

63.

Cheung, S. T., Cheung, P. F., Cheng, C. K., Wong, N. C., & Fan, S. T. (2011). Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology, 140(1), 344–355. doi:10.1053/j.gastro.2010.07.049.PubMedCrossRef

64.

Frank, N. Y., Margaryan, A., Huang, Y., Schatton, T., Waaga-Gasser, A. M., Gasser, M., et al. (2005). ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Research, 65(10), 4320–4333. doi:10.1158/0008-5472.CAN-04-3327.PubMedCrossRef

65.

Wei, J., Barr, J., Kong, L. Y., Wang, Y., Wu, A., Sharma, A. K., et al. (2010). Glioma-associated cancer-initiating cells induce immunosuppression. Clinical Cancer Research, 16(2), 461–473. doi:10.1158/1078-0432.CCR-09-1983.PubMedCrossRef

66.

Ramgolam, K., Lauriol, J., Lalou, C., Lauden, L., Michel, L., de la Grange, P., et al. (2011). Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function. PLoS One, 6(4), e18784. doi:10.1371/journal.pone.0018784.PubMedCrossRef

67.

Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M., & Morrison, S. J. (2008). Efficient tumour formation by single human melanoma cells. Nature, 456(7222), 593–598. doi:10.1038/nature07567.PubMedCrossRef

68.

Pang, R., Law, W. L., Chu, A. C., Poon, J. T., Lam, C. S., Chow, A. K., et al. (2010). A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell, 6(6), 603–615. doi:10.1016/j.stem.2010.04.001.PubMedCrossRef

69.

Marsh, D., Suchak, K., Moutasim, K. A., Vallath, S., Hopper, C., Jerjes, W., et al. (2011). Stromal features are predictive of disease mortality in oral cancer patients. The Journal of Pathology, 223(4), 470–481. doi:10.1002/path.2830.PubMedCrossRef

Title: Cancer stem cells and EMT in carcinoma
Authors: Adrian Biddle
Ian C. Mackenzie
Publication date: 01-06-2012
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1-2/2012
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-012-9345-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2012

Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression

Biological influence of Hakai in cancer: a 10-year review

BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype

Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism

Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?

Regulation of p53 by ING family members in suppression of tumor initiation and progression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer